BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rhodes T, Lancaster K, Harris M, Treloar C. Evidence-making controversies: the case of hepatitis C treatment and the promise of viral elimination. Critical Public Health 2018;29:260-73. [DOI: 10.1080/09581596.2018.1459475] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
Number Citing Articles
1 Rhodes T, Lancaster K. Evidence-making interventions in health: A conceptual framing. Social Science & Medicine 2019;238:112488. [DOI: 10.1016/j.socscimed.2019.112488] [Cited by in Crossref: 47] [Cited by in F6Publishing: 34] [Article Influence: 15.7] [Reference Citation Analysis]
2 Lancaster K, Ritter A, valentine K, Rhodes T. “A more accurate understanding of drug use”: A critical analysis of wastewater analysis technology for drug policy. International Journal of Drug Policy 2019;63:47-55. [DOI: 10.1016/j.drugpo.2018.10.011] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
3 Seear K, Fraser S, Farrugia A, valentine K. Beyond a ‘post-cure’ world: Sketches for a new futurology of hepatitis C. International Journal of Drug Policy 2021;94:103042. [DOI: 10.1016/j.drugpo.2020.103042] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Hedges K, Lasco G. Medical Populism and COVID-19 Testing. Open Anthropological Research 2021;1:73-86. [DOI: 10.1515/opan-2020-0109] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Ekendahl M, Karlsson P. Fixed and fluid at the same time: how service providers make sense of relapse prevention in Swedish addiction treatment. Critical Public Health. [DOI: 10.1080/09581596.2021.1951170] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Pienaar K, Petersen A, Bowman DM. Managing risks or generating uncertainties? Ambiguous ontologies of testing in Australian healthcare. Health (London) 2021;25:669-87. [PMID: 32186208 DOI: 10.1177/1363459320912830] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Lancaster K, Rhodes T, Rance J. "Towards eliminating viral hepatitis": Examining the productive capacity and constitutive effects of global policy on hepatitis C elimination. Int J Drug Policy 2020;80:102419. [PMID: 30975593 DOI: 10.1016/j.drugpo.2019.02.008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
8 Weier M, Farrugia A. 'Potential issues of morbidity, toxicity and dependence': Problematizing the up-scheduling of over-the-counter codeine in Australia. Int J Drug Policy 2020;80:102538. [PMID: 31362859 DOI: 10.1016/j.drugpo.2019.07.033] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
9 Holt M, Newman CE, Lancaster K, Smith AK, Hughes S, Truong HM. HIV pre-exposure prophylaxis and the 'problems' of reduced condom use and sexually transmitted infections in Australia: a critical analysis from an evidence-making intervention perspective. Sociol Health Illn 2019;41:1535-48. [PMID: 31215066 DOI: 10.1111/1467-9566.12967] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
10 Rhodes T, Lancaster K. Evidence-making hepatitis C cure: Towards a science that knows more carefully. Int J Drug Policy 2019;72:40-6. [PMID: 31307851 DOI: 10.1016/j.drugpo.2019.06.023] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]